LLLingli Li

Lingli Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lingli Li has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Guang Chen

    Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

    4 shared publications
  • Yi Zhou

    Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    3 shared publications
  • Fuer Lu

    Department of Integrated Traditional Chinese and Western Medicine, Tongji Medical College, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China

    2 shared publications
  • Jinlong Luo

    Department of Emergency Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, PR China; Department of Critical Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, PR China

    2 shared publications
  • Xinyu Xiong

    Department of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, People’s Republic of China

    2 shared publications
  • Xueping Yang

    Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China

    2 shared publications

Latest Publications

  • Open Access

    An explainable machine learning model for predicting one-year osteoporosis risk: development and validation in a prospective cohort

    by Jinyi Wu, Dan Yu, Dan Huang, Chunyan Yin, Lingli Li

    This study aimed to develop and validate an interpretable machine learning model using readily available biochemical indicators to predict the 1-year risk of osteoporosis, thereby offering an efficient and accessible alternative to tools like FRAX and resource-intensive methods like radiomics. A prospective cohort study was conducted using electronic medical records from a hospital in Wuhan, China (Jan 2020-Jan 2025). Patients with at least two DXA scans and blood tests were included. After data cleaning and handling missing values, 40 initial features were analyzed. Feature selection involved LASSO and univariate regression. Eleven machine learning models were developed and compared, with XGBoost ultimately selected. Model performance was evaluated using AUC, sensitivity, specificity, etc., on internal and external validation sets. SHAP analysis provided model interpretability. The final model was deployed as an online tool. The final model utilized only 17 routinely available features. The XGBoost model demonstrated superior performance, achieving an AUC of 0.966 for predicting 1-year spine osteoporosis in the derivation set. This high performance was consistently replicated in the external validation set (AUC = 0.969). The model also showed robust predictive power for left and right hip osteoporosis. SHAP analysis confirmed the strong influence of age and gender, among other features, and provided both global and local interpretations. This study successfully developed a highly accurate, interpretable, and clinically practical machine learning model for 1-year osteoporosis prediction using only 17 routine clinical features. Its performance surpasses many previous models and is comparable to complex radiomics-based approaches, while being far more accessible. The online tool facilitates clinical application, offering a valuable and efficient strategy for early osteoporosis screening and risk assessment.

  • Open Access

    Acupoint Catgut Embedding Alleviates High-Fat-Diet Induced Obesity Through Activating Wnt/β-Catenin Pathway

    by Lu Chen, Yi Zhou, Yuhang Chen, Yun Wang, Jinqing Hu, Lingli Li

    Objective: This study was designed to assess the effect and explore the underlying mechanism of acupoint catgut embedding on high-fat-diet (HFD) induced obese mice. Methods: The therapeutic effect of acupoint catgut embedding was evaluated by the food intake, body weight and glycolipid metabolism. The size, number, and morphology of adipocytes were observed by histological staining. The targets in acupoint catgut embedding for treating obesity were detected by RNA-seq. The protein levels of Wnt1 and β-catenin in epididymal adipose tissue (eWAT) were detected by Western blot. Results: Acupoint catgut embedding significantly reduced body weight, improve glucose tolerance and ameliorate insulin resistance, diminish serum total cholesterol and triglyceride levels in HFD-induced obese mice, and inhibited excessive adipocyte hypertrophy in eWAT. Acupoint catgut embedding significantly up-regulated Wnt1 and β-catenin protein levels in eWAT. Conclusion: Acupoint catgut embedding can reduce body weight, attenuate insulin resistance and dyslipidemia, suppress adipocyte hypertrophy of eWAT in HFD-induced obese mice. The mechanism could be related to the activation of Wnt/β-catenin pathway. Graphical


  • Open Access

    Ginsenoside Rb1 Alleviates DSS-Induced Ulcerative Colitis by Protecting the Intestinal Barrier Through the Signal Network of VDR, PPARγ and NF-κB

    by Yi Zhou, Xinyu Xiong, Zhe Cheng, Zekai Chen, Shizhen Wu, Yan Yu, Yujin Liu, Guang Chen, Lingli Li

    Purpose: Ginseng (Panax ginseng Meyer) is an herbal medicine used in traditional Chinese medicine (TCM), has the effects of treating colitis and other diseases. Ginsenoside Rb1 (GRb1), a major component of ginseng, modulates autoimmunity and metabolism. However, the mechanism underlying GRb1 treatment of ulcerative colitis (UC) has not yet been elucidated. UC is a refractory inflammatory bowel disease (IBD) with a high recurrence rate, and researches on new drugs for UC have been in the spotlight for a long time. Methods: Mice with DSS-induced UC were treated with GRb1 or 0.9% saline for 10 days. Colon tissue of UC mice was collected to detect the levels of intestinal inflammatory cytokines and integrity of the intestinal barrier. RNA-seq and network pharmacology were used to predict the therapeutic targets of GRb1 during UC treatment. Results: GRb1 treatment alleviated intestinal inflammation and improved intestinal barrier dysfunction in UC mice. Specifically, GRb1 downregulated the levels of pro-inflammatory cytokines such as TNF-α and IL-6, while upregulating the level of the anti-inflammatory cytokine IL-10. Additionally, GRb1 treatment increased the levels of tight junction proteins including ZO-1, Occludin, and E-cadherin, which are crucial for maintaining intestinal barrier integrity. Further analyses using RNA-seq and network pharmacology suggested that these effects might involve the regulation of GRb1 in the signal transduction network of VDR, PPARγ, and NF-κB. Conclusion: The study demonstrated that GRb1 effectively alleviated UC by modulating intestinal inflammation and protecting the integrity of the intestinal barrier through the signal transduction network of VDR, PPARγ, and NF-κB.


  • Open Access

    6-gingerol ameliorates metabolic disorders by inhibiting hypertrophy and hyperplasia of adipocytes in high-fat-diet induced obese mice

    by Zhe Cheng, Xinyu Xiong, Yi Zhou, Fan Wu, Qingqing Shao, Ruolan Dong, Qiong Liu, Lingli Li, Guang Chen


  • Open Access

    Wu-Mei-wan protects pancreatic β cells by inhibiting NLRP3 Inflammasome activation in diabetic mice

    by Xueping Yang, Fuer Lu, Lingli Li, Jingbin Li, Jinlong Luo, Siyi Zhang, Xinqiao Liu, Guang Chen

    Wu-Mei-Wan (WMW) is a traditional Chinese herbal formulation that is clinically prescribed to treat diabetes mellitus in China. WMW has been shown to alleviate damage in pancreatic β cells, but the underlying mechanism remains unclear. This study aims to explore how WMW plays a protective role in pancreatic islets. Drug testing and mechanism analyses were performed on mice treated with three concentrations of WMW (4800, 9600, and 19,200 mg/kg/bw) for four consecutive weeks. Blood was collected from both db/db and wild-type mice to determine fasting blood glucose (FBG) and serum insulin levels. The expression of proteins related to apoptosis, cysteinyl aspartate-specific proteinase 12 (caspase-12) and B-cell leukemia 2 (Bcl-2), was measured by western blot. Interleukin-1β (IL-1β), interleukin-18 (IL-18), monocyte chemoattractant protein-1α (MCP-1α), and tumor necrosis factor-α (TNF-α) in the pancreas were tested with enzyme-linked immunosorbent assay (ELISA). Immunohistochemistry staining of F4/80 was performed to measure the pancreatic infiltration of macrophages. Western blot and immunofluorescence staining of the NLRP3 inflammasome were used to measure the expression of proteins related to apoptosis and inflammation. WMW dose-dependently reduced FBG and promoted serum insulin secretion in db/db mice compared to the wild-type controls. WMW protected pancreatic β cells with a pattern of decreasing caspase-12 and increasing Bcl-2 expression. WMW also reversed the upregulated production of IL-1β, IL-18, MCP-1α, and macrophage-specific surface glycoprotein F4/80 in diabetic mice. In addition, the protein expression levels of NLRP3 inflammasome components NLRP3, ASC, and caspase-1 (P20) were higher in db/db mice than in wild-type controls. WMW inhibits the activation of the NLRP3 inflammasome to protect pancreatic β cells and prevent type 2 diabetes mellitus development.


  • Open Access

    Jia-Wei-Jiao-Tai-Wan ameliorates type 2 diabetes by improving β cell function and reducing insulin resistance in diabetic rats

    by Guang Chen, Xueping Yang, Xiaoyu Yang, Lingli Li, Jinlong Luo, Hui Dong, Lijun Xu, Ping Yi, Kaifu Wang, Xin Zou, et al.

    Jia-Wei-Jiao-Tai-Wan (JWJTW), composed of Jiao-Tai-Wan (Cinnamomum cassia and Rhizoma coptidis) and other antidiabetic herbs, including Astragalus membranaceus, Herba Gynostemmatis, Radix Puerariae Lobatae, Folium Mori and Semen Trigonellae, is widely used to treat diabetes and has demonstrated a curative effect in the clinic, but the potential mechanism is unknown. This study aimed to explore the effects of JWJTW on diabetic rats and to clarify the underlying mechanism. JWJTW was prepared, and the main components contained in the formula were identified by high-performance liquid chromatography (HPLC) fingerprint analysis. Diabetic rats induced by streptozotocin (STZ) and a high-sucrose-high-fat diet were treated with two concentrations of JWJTW (1.025 and 2.05 g/kg/d) for 100 days. The oral glucose tolerance test (OGTT), insulin release test (IRT) and insulin tolerance test (ITT) were performed to measure the glycometabolism of the diabetic rats at the end of the treatment period. Blood was collected to determine the serum lipid levels of the diabetic rats. Nitric oxide (NO), malondialdehyde (MDA), superoxide dismutase (SOD) and glutathione peroxidase (GSH-px) were detected in pancreas homogenates to analyze the oxidative stress in the pancreata of diabetic rats, and the expression levels of pancreatic and duodenal homeobox 1 (PDX-1) and insulin in the pancreas were tested by Western blot to measure pancreatic islet function. In addition, Western blots were used to measure the expression of proteins related to the insulin signaling pathway in skeletal muscle of the diabetic rats. The results showed that the administration of JWJTW could ameliorate impairments in glucose tolerance, insulin release function and insulin tolerance in diabetic rats. JWJTW could also dose-dependently reduce serum lipid levels in diabetic rats. JWJTW restrained oxidative stress by decreasing the expression of NO and MDA and increasing the expression of SOD and GSH-px. JWJTW improved the function of pancreatic β cells by increasing PDX-1 and insulin expression. In addition, JWJTW restored the impaired insulin signaling; upregulated phospho-insulin receptor (pInsR) expression, insulin receptor substrate (IRS) tyrosine phosphorylation, phosphatidylinositol 3-kinase (PI3K) (p85), and glucose transporter 4 (GLUT4) expression; and downregulated the serine phosphorylation of IRS. This study suggests that JWJTW can ameliorate type 2 diabetes by improving β cell function and reducing insulin resistance in diabetic rats.